Recommendation Updates

Follow the latest news on active Turnaround Letter purchase recommendations.

Mid Cap / Pharmaceuticals, Biotechnology & Life Sciences

Boston Scientific Asia-Pacific Reallignment Announced

On January 31, 2012, Boston Scientific Corporation (NYSE: BSX) announced creation of its Asia-Pacific regional organization that includes Australia, New Zealand, China, Hong Kong, India, Japan, South Korea, South East Asia, Taiwan and Turkey. The company believes this pan-Asia business model will help drive growth by leveraging best practices in the region, accessing the strong pool of local talent and collaborating with healthcare professionals and regulatory agencies throughout the region. The organization will be led by Supratim Bose, Executive Vice President and President, Asia-Pacific for Boston Scientific. Before joining Boston Scientific in January 2012, Mr. Bose was Founder and Chief Executive Officer of Singapore-based Bose Consulting Group, which specialized in strategic management consulting services for the healthcare industry. Previously, he worked for nearly 30 years at Johnson & Johnson, where he concluded his tenure as the Company Group Chairman of its Medical Devices and Diagnostics business in 2009. In this role, he managed Johnson & Johnson’s MD&D companies throughout Asia-Pacific, including Japan, having pioneered its entry in all emerging markets in Asia, including China, India and Vietnam.

Read More Purchase Recommendation Updates

Identify & Profit from Distressed Investing

Free Report: Turnaround Investing Mistakes

Turnaround Investing Blog

Turnaround Investing Blog

Is there value in bankrupt PG&E’s stock?

In nearly every case, the shares of a company in bankruptcy become worthless. In very rare cases, however, they can become great investments. W.R. Grace (NYSE:GRA) shares produced a 75-fold return, as an example. With California utility PG&E (NYSE:PCG) now in bankruptcy, the range of possible outcomes for its equity is wide.

Read More.

EV/EBITDA: What Is It & Why Are We Using It More?

In reading recent editions of The Turnaround Letter, you have probably noticed that we are increasingly using EV/EBITDA as a valuation measure, rather than the better-known price/earnings multiple.  We thought it might be useful to describe this measure and why we like it.

Read More.

Turnaround Letter Stock Pick Named Top Performer of 2017

 

stock market advicex

 

What Last Year's Top Stock Pickers Are Buying in 2018

 

This Forbes write-up follows up on the recent Top Stock Tips report--naming The Turnaround Letter's Crocs recommendation the top performer of 2017: With 90% gains, CROX beat out 100 other investment ideas included in the report; and the stock continues to have value investing appeal, according to Putnam.

 

George notes, "We see additional upside for the stock in 2018 as management's efforts continue to bear fruit, though the gains will likely be more muted than we saw in 2017."